CONTINUOUS GLUCOSE MONITORING ALLOWS AN EFFICIENT DISCLOSURE
OF TIME SPENT IN HYPERGlyCExIA IN NON DIABETIC PATIENTS ADMITTED
FOR ACUTE CORONARY SYNDROME IN INTENSIVE CARE UNIT (ICU)

R.P. Radermecker (1,2), A. Sultan (3), C. Plot (4), A. Saint Remy (5), A. Avignon (3), E. Renard (1).
(1) Department of Endocrine diseases, Hôpital Lapeyronie, 34295 Montpellier cedex 5, France. 
(2) Department of Diabetes, Nutrition and Metabolic disorders, CHU Sart Tilman, University of 
Liège, 4000 Liège, Belgium. (3) Department of Metabolic diseases, Hôpital Lapeyronie, 34295 
Montpellier cedex 5, France. (4) Department of Cardiology B, ICU, Hôpital Arnaud de Villeneuve, 
34295 Montpellier cedex 5, France.

Tight normoglycaemia improves medical prognosis of acute coronary syndromes (ACS). Therefore, 
detection of hyperglycaemic deviations is crucial to initiate and adapt insulin therapy in patients who 
are naive for diabetes with no high blood glucose when admitted. 
We evaluated the ability to identify time spent over 140 mg/dl (TS>140) by using a continuous glucose 
monitoring device in a series of patients admitted in ICU for ACS. The secondary objective was to look 
for predictive factors of hyperglycaemia. 
A subcutaneous glucose sensor connected to a portable monitor (CGMS®, MiniMed-Medtronic) was 
used in 21 patients (17 M/ 4 F), aged 60 ± 13, with a BMI of 26 ± 3 kg/m², admitted in ICU since less 
than 48 hours. Average time of recording was 40 hours per patient (2400 min). Sensor calibrations 
were performed against the 4 daily capillary blood glucose (CBG) measurements checked in clinical 
routine.
From a cumulated recording time of 50410 min, sensor data showed a TS>140 of 9565 min (17% of 
total time). Although a significant correlation appeared between the number of CBG values >140 
mg/dl and TS>140 mg/dl (r = 0.93; p< 0.001), only 22/136 CBG values were >140 mg/dl in patients 
presenting some time >140 mg/dl (n=17). No significant correlation between TS>140 mg/dl and age, 
sex, BMI or family history of CV disease or diabetes was disclosed. From a multivariate analysis, the 
model shows only a trend for BMI as a predictive factor for hyperglycaemia (p=0.056; B coefficient = 0.42).
Our results show a better ability for CGMS® to detect hyperglycaemic periods than routine CBG 
measurements in non diabetic patients, showing no high blood glucose when admitted for ACS. 
Because no clear predictive factor for hyperglycaemic deviations could be pointed out, continuous 
glucose monitoring looks valuable in such patients. Recently developed continuous glucose monitoring 
deVICES providing real-time data might be useful tools to track and manage hyperglycaemia in ACS.
26th Workshop of the AIDPIT Study Group
1st European Diabetes Technology and Transplantation Meeting

February 4-6, 2007
Montpellier
France

FINAL PROGRAM AND ABSTRACTS